Effects of weight loss and pharmacotherapy on inflammatory markers of cardiovascular disease

References

• Libby P. Inflammation in atherogenesis. Nature 420, 868–874 (2003).
   Google Scholar
• Sonnenberg GE, Krakower GR, Kissebah AH. A novel pathway to the manifestations of metabolic syndrome. Obes. Res. 12, 180–186 (2004).
   PubMedGoogle Scholar
• Pittas AG, Joseph NA. Adipocytokines and insulin resistance. J. Clin. Endocrinol. Metabol. 89, 447–452 (2004).
   PubMed Web of Science ®Google Scholar
• Wisse BE. The inflammatory syndrome: The role of adipose tissue cytokines in metabolic disorders linked to obesity. J. Am. Soc. Nephrol. 15(11), 2792–2800 (2004).
   PubMed Web of Science ®Google Scholar
• Engeli S, Schling P, Gorzelniak K et al. The adipose-tissue rennin–angiotensin– aldosterone system: role in the metabolic syndrome? Int. J. Biochem. Cell. Biol. 35, 807–825 (2003).
   PubMed Web of Science ®Google Scholar
• Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of Type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J. Clin. Endocrinol. Metabol. 89(6), 2601–2607 (2004).
   PubMed Web of Science ®Google Scholar
• Ziccardi P, Nappo F, Giugliano G et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 105, 804–809 (2002).
   PubMed Web of Science ®Google Scholar
• Fruhbeck G. The adipose tissue as a source of vasoactive factors. Curr. Med. Chem. Cardiovasc. Hematol. Agents 2(3), 197–208 (2004).
   PubMedGoogle Scholar
• Einhorn D, Aroda VR, Henry R. Glitazones and the management of insulin resistance: what they do and how might they be used. Endocrinol. Metab. Clin. N. Am. 33, 595–616 (2004).
   PubMedGoogle Scholar
• Ross R. Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 340, 115–126 (1999).
   PubMed Web of Science ®Google Scholar
• Bataille R, Klein B. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum. 35, 982–984 (1992).
   Google Scholar
• Mohamed-Ali V, Goodrick S, Rawesh A et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. J. Clin. Endocrinol. Metabol. 82, 4196–4200 (1997).
   PubMed Web of Science ®Google Scholar
• Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J. Clin. Endocrinol. Metabol. 83, 847–850 (1998).
   PubMed Web of Science ®Google Scholar
• Bastard JP, Jardel C, Bruckert E et al. Elevated levels of interleukin-6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J. Clin. Endocrinol. Metabol. 85, 3338–3342 (2000).
   PubMed Web of Science ®Google Scholar
• Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem. J. 265, 621–636 (1990).
   PubMed Web of Science ®Google Scholar
• Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J. Clin. Invest. 11, 1805–1812 (2003).
   Google Scholar
• Burstein SA, Peng J, Friese P et al. Cytokine-induced alteration of platelet and hemostatic function. Stem Cells 14(Suppl.1), 154–162 (1996).
   PubMedGoogle Scholar
• Wassman S, Stumpf M, Strehlow K et al. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II Type 1 receptor. Circ. Res. 94, 534–541 (2004).
   Google Scholar
• Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of Type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J. Clin. Endocrinol. Metabol. 89(6), 2601–2607 (2004).
   PubMed Web of Science ®Google Scholar
• Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 404, 661–671 (2000).
   PubMed Web of Science ®Google Scholar
• Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell 116, 337–350 (2004).
   PubMed Web of Science ®Google Scholar
• Gainsford T, Willson TA, Metcalf D et al. Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells. Proc. Natl Acad. Sci. USA 93, 14564–14568 (1996).
   PubMed Web of Science ®Google Scholar
• Raso GM, Pacilio M, Esposito E, Coppola A, Di Carlo R, Meli R. Leptin potentiates IFN-γ-induced expression of nitric oxide synthase and cyclo-oxygenase-2 in murine macrophage J774A. 1. Br. J. Pharmacol. 187, 799–804 (2002).
   Google Scholar
• Bornstein SR, Licinio J, Tauchnitz R et al. Plasma leptin levels are increased in survivors of acute sepsis: Associated loss of diurnal rhythm, in cortisol and leptin secretion. J. Clin. Endocrinol. Metabol. 83, 280–283 (1998).
   PubMed Web of Science ®Google Scholar
• Hasty AH, Shimano H, Osuga J et al. Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. J. Biol. Chem. 276, 37402–37408 (2001).
   PubMed Web of Science ®Google Scholar
• Wallace AM, McMahon AD, Packard CJ et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 104, 3052–3056 (2001).
   PubMed Web of Science ®Google Scholar
• Shamsuzzaman ASM, Winnicki M, Wolk R et al. Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation 109, 2181–2185 (2004).
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J. Clin. Invest. 95, 2409–2415 (1995).
   PubMed Web of Science ®Google Scholar
• Tsigos C, Kyrou I, Chala E et al. Circulating tumor necrosis factor-α concentrations are higher in abdominal versus peripheral obesity. Metabolism 48, 1332–1335 (1999).
   PubMed Web of Science ®Google Scholar
• Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue: Relation to obesity, insulin resistance, and tumor necrosis factor-α expression. Diabetes 52, 1779–1785 (2003).
   PubMed Web of Science ®Google Scholar
• Ruan H, Lodish HF. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-α. Cytokine Growth Factor Rev. 14, 447–455 (2003).
   PubMed Web of Science ®Google Scholar
• Samad F, Teoman K, Wiesbrock SM et al. Tumor necrosis factor α is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. Proc. Natl Acad. Sci. USA 96, 6902–6907 (1999).
   PubMed Web of Science ®Google Scholar
• Yudkin JS, Stehouwer CDA, Emeis JJ et al. C-reactive protein in healthy subjects: associations with obesity insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue. Arterioscler. Thromb. Vasc. Biol. 19, 972–978 (1999).
   PubMed Web of Science ®Google Scholar
• Skurk T, Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int. J. Obes. Relat. Metab. Disord. 28(11), 1357–1364 (2004).
   PubMed Web of Science ®Google Scholar
• Halleux CM, Declerck PJ, Tran SL, Detry R, Brichard SM. Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines. J. Clin. Endocrinol. Metabol. 84, 4097–4105 (1999).
   PubMed Web of Science ®Google Scholar
• Takahashi D, Tamura K, Ushikubo T et al. Relationship between hepatic angiotensinogen mRNA expression and plasma angiotensinogen in patients with chronic hepatitis. Life Sci. 60, 1623–1633 (1997).
   PubMed Web of Science ®Google Scholar
• Schorr U, Blaschke K, Turan S et al. Relationship between angiotensinogen, leptin and blood pressure levels in young normotensive men. J. Hypertens. 16, 1475–1480 (1998).
   PubMed Web of Science ®Google Scholar
• Tamura K, Umemura S, Yamakawa T et al. Modulation of tissue angiotensinogen gene expression in genetically obese hypertensive rats. Am. J. Physiol. 272, R1704–1711 (1997).
   Google Scholar
• Van Harmelen V, Ariapart P, Hoffstedt J et al. Increased adipose angiotensinogen gene expression in human obesity. Obes. Res. 8(4) 337–341 (2000).
   PubMedGoogle Scholar
• Schieffer B, Drexler H. Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular disease. Am. J. Cardiol. 91(Suppl.), 12H–18H (2003).
   Google Scholar
• Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotenin IV. J. Clin. Invest. 96, 2515–2520 (1995).
   PubMed Web of Science ®Google Scholar
• Schieffer B, Luchtefeld M, Braun S, Hilfiker A, Hilfiker-Kleiner D, Drexler H. Role of NAD(P)H oxidase in angiotensin II-induces JAK/STAT signaling and cytokine induction. Circ. Res. 87, 1195–1201 (2000).
   PubMed Web of Science ®Google Scholar
• Kranzhöfer R, Schmidt J, Pfeiffer CAH, Hagl S, Libby P, Kübler W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 19, 1623–1629 (1999).
   PubMed Web of Science ®Google Scholar
• Goldstein BJ, Scalia R. Adiponectin: A novel adipokine linking adipocytes and vascular function. J. Clin. Endocrinol. Metabol. 89(6), 2563–2568 (2004).
   PubMed Web of Science ®Google Scholar
• Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care 26, 2442–2450 (2003).
   PubMed Web of Science ®Google Scholar
• Ouchi N, Kihara S, Arita Y et al. Novel modulator for endothelial adhesion molecules: adipocyte derived plasma protein adiponectin. Circulation 100, 2473–2476 (1999).
   PubMed Web of Science ®Google Scholar
• Hotta K, Funahashi T, Arita Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in Type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol. 20, 1595–1599 (2000).
   PubMed Web of Science ®Google Scholar
• Tan KC, Xu A, Chow WS. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J. Clin. Endocrinol. Metabol. 89, 765–769 (2004).
   PubMed Web of Science ®Google Scholar
• Ouchi N, Ohishi M, Kihara S et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 42, 231–234 (2003).
   PubMed Web of Science ®Google Scholar
• Shimabukuro M, Higa N, Asahi T. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J. Clin. Endocrinol. Metabol. 88, 3236–3240 (2003).
   PubMed Web of Science ®Google Scholar
• Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J. Biol. Chem. 278, 45021–45026 (2003).
   PubMed Web of Science ®Google Scholar
• Brakenhielm E, Veitonmaki N, Cao R et al. Adiponectin-induced anti-angiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc. Natl Acad. Sci. USA 101, 2476–2481 (2004).
   PubMed Web of Science ®Google Scholar
• Rajala MW, Scherer PE. Minireview: the adipocyte – at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144, 3765–3773 (2003).
   PubMed Web of Science ®Google Scholar
• Sniderman AD, Maslowska M, Cianflone K. Of mice and men (and women) and the acylation-stimulating protein pathway. Curr. Opin. Lipidol. 11, 291–296 (2000).
   Google Scholar
• Cottam DR, Mattar SG, Barinas-Mitchell E et al. The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effects of weight loss. Obes. Surg. 14, 589–600 (2004).
   PubMed Web of Science ®Google Scholar
• Garg A. Dyslipoproteinemia and diabetes. Endocrinol. Metab. Clin. N. Am. 27(3), 613–626 (1998).
   PubMedGoogle Scholar
• Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. High triglycerides and low HDL-C cholesterol and blood pressure and risk of ischemic heart disease. Hypertension 36, 226–232 (2000).
   PubMed Web of Science ®Google Scholar
• Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release. J. Clin. Invest. 94, 1172–1179 (1994).
   PubMed Web of Science ®Google Scholar
• McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 43, 104–109 (1994).
   PubMed Web of Science ®Google Scholar
• Einhorn D, Reaven GM, Cobin RH et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr. Pract. 9(3), 237–252 (2003).
   PubMedGoogle Scholar
• Lemieux I, Pascot A, Prud’homme D et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler. Thromb. Vasc. Biol. 21, 961–967 (2001).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342, 836–843 (2000).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Morrow DA. C-reactive protein, inflammation, and coronary risk. Cardiol. Clin. 21, 315–325 (2003).
   PubMedGoogle Scholar
• Van der Meer IM, de Maat MPM, Hak AE et al. C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree. The Rotterdam Study. Stroke 33, 2750–2755 (2002).
   PubMedGoogle Scholar
• Danesh J, Whincup P, Walker M et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. Br. Med. J. 321, 199–204 (2000).
   PubMed Web of Science ®Google Scholar
• Danesh J, Wheeler JG, Hirschfield GM et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350, 1387–1397 (2004).
   PubMed Web of Science ®Google Scholar
• Roberts WL, Moulton L, Law TC et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin. Chem. 47, 418–425 (2001).
   PubMed Web of Science ®Google Scholar
• Pearson TA, Mensah GA, Alexander RW et al. AHA/CDC Scientific Statement: markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107, 499–511 (2003).
   PubMed Web of Science ®Google Scholar
• Burke AP, Tracy RP, Kolodgie F et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation 105, 2019–2023 (2002).
   PubMed Web of Science ®Google Scholar
• Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102, 2165–2168 (2000).
   PubMed Web of Science ®Google Scholar
• Pasceri V, Cheng JS, Willerson JT et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 103, 2531–2534 (2001).
   PubMed Web of Science ®Google Scholar
• Verma S, Li SH, Badiwala MV et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 105, 1890–1896 (2002).
   PubMed Web of Science ®Google Scholar
• Nakagomi A, Freedman SB, Geczy CL. Interferon-γ and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, and hormone replacement treatment. Circulation 101, 1785–1791 (2000).
   PubMed Web of Science ®Google Scholar
• Mousa SA, Bozarth JM. Inhibitory effect of C-reactive protein on the release of tissue factor pathway inhibitor from human endothelial cells: reversal by low molecular weight heparin. J. Am. Coll. Cardiol. 38, 202A (2002).
   Google Scholar
• Devarai S, Xu DY, Jiala I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 107, 398–404 (2003).
   Google Scholar
• Venuogopal SK, Devarai S, Yuhanna I et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 106, 1439–1441 (2002).
   Google Scholar
• Verma S, Wang CH, Li SH et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106, 913–919 (2002).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med.352(1), 73–75 (2005).
   Google Scholar
• Torgerson JS, Carlsson B, Stenlof K, Carlsson LM, Bringman E, Sjostrom L. A low serum leptin level at baseline and a large early decline in leptin predict a large 1-year weight reduction in energy-restricted obese humans. J. Clin. Endocrinol. Metabol. 84(11), 4197–4204 (1999).
   PubMed Web of Science ®Google Scholar
• Brook RD, Bard RL, Glazewski L et al. Effect of a short-term weight loss on the metabolic syndrome and conduit vascular endothelial function in overweight adults. Am. J. Cardiol. 83, 1012–1016 (2004).
   Google Scholar
• Liu YM, Lacorte JM, Viguerie N et al. Adiponectin gene expression in subcutaneous adipose tissue of obese women in response to short-term very low calorie diet and refeeding. J. Clin. Endocrin. Metabol. 88(12), 5881–5886 (2003).
   PubMed Web of Science ®Google Scholar
• Xydakis AM, Case CC, Jones PH et al. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J. Clin. Endocrinol. Metabol. 89(6), 2697–2703 (2004).
   Google Scholar
• Seshadri P, Iqbal N, Stern L et al. A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity. Am. J. Med. 117, 398–405 (2004).
   PubMed Web of Science ®Google Scholar
• ATP III Final Report. II. Rationale for intervention. Circulation 106, 3163–3223 (2002).
   Google Scholar
• Heilbronn LK, Noakes M, Clifton PM. Energy restriction and weight loss on very-low fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler. Thromb. Vasc. Biol. 21, 968–970 (2001).
   PubMed Web of Science ®Google Scholar
• Fontana L, Meyer TE, Klein S, Holloszy JO. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc. Natl Acad. Sci. 101(17), 6659–6663 (2004).
   PubMed Web of Science ®Google Scholar
• Nicklas BJ, Ambrosius W, Messier SP et al. Diet-induced weight loss, exercise, and chronic inflammation in older, obese adults: a randomized controlled clinical trial. Am. J. Clin. Nutr. 79, 544–551 (2004).
   PubMed Web of Science ®Google Scholar
• You T, Berman DM, Ryan AS, Nicklas BJ et al. Effects of hypocaloric diet and exercise training on inflammation and adipocyte lipolysis in obese postmenopausal women. J. Clin. Endocrinol. Metabol. 89, 1739–1746 (2004).
   PubMed Web of Science ®Google Scholar
• Kasapis C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammatory markers. J. Am. Coll. Cardiol. 45, 1563–1569 (2005).
   PubMed Web of Science ®Google Scholar
• Van Dielen FMH, Buurman WA, Hadfoune M, Nijhuis J, Greve JW. Macrophage inhibitory factor, plasminogen activator inhibitor-1, other acute phase proteins, and inflammatory mediators normalize as a result of weight loss in morbidly obese subjects treated with gastric restrictive surgery. J. Clin. Endocrinol. Metabol. 89, 4062–4068 (2004).
   PubMed Web of Science ®Google Scholar
• Vásquez LA, Pazos F, Berrazueta JR et al. Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. J. Clin. Endocrinol. Metabol. 90, 316–322 (2005).
   Google Scholar
• Sharman MJ, Volek JS. Weight loss leads to reductions in inflammatory biomarkers after a very-low-carbohydrate diet and a low-fat diet in overweight men. Clin. Sci. (Lond.) 107(4), 365–369 (2004).
   PubMed Web of Science ®Google Scholar
• Bastard JP, Jardel C, Bruckert E et al. Elevated levels of interleukin-6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J. Clin. Endocrinol. Metabol. 85, 3338–3342 (2000).
   PubMed Web of Science ®Google Scholar
• Jarvi AE, Karlstrom BE, Granfeldt YE et al. Improved glycemic control and lipid profile and normalized fibrinolytic activity on a low-glycemic index diet in Type 2 diabetic patients. Diabetes Care 22, 10–18 (1999).
   PubMed Web of Science ®Google Scholar
• Colwell JA. Treatment for the procoagulant state in Type 2 diabetes. Endocrinol. Metab. Clin. N. Am. 30(4), 1011–1030 (2001).
   Google Scholar
• Harp JB, Henry SA, DiGirolamo M. Dietary weight loss decreases serum angiotensin-converting enzyme activity in obese adults. Obes. Res. 10(10), 985–990 (2002).
   PubMedGoogle Scholar
• Tsai AG, Wadden T. Systematic review: an evaluation of major commercial weight loss programs in the United States. Ann. Intern. Med. 142, 56–66 (2005).
   PubMed Web of Science ®Google Scholar
• Hannum SM, Carson L, Evans EM et al. Use of portion-controlled entrees enhances weight loss in women. Obes. Res. 12, 538–546 (2004).
   Google Scholar
• Buchwald H, Avidor Y, Braunwald E et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 292(14), 1724–1737 (2004).
   PubMed Web of Science ®Google Scholar
• Sjöström L, Lindroos AK, Peltonen M et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med. 351, 2683–2693 (2004).
   PubMed Web of Science ®Google Scholar
• Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int. J. Obes. Relat. Metab. Disord. 27, 1437–1446 (2003).
   PubMed Web of Science ®Google Scholar
• Korner J, Aronne LJ. Pharmacological approaches to weight reduction: Therapeutic targets. J. Clin. Endocrinol. Metabol. 89(6), 2616–2621 (2004).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336, 973–979 (1997).
   PubMed Web of Science ®Google Scholar
• Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased pro-inflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 100, 793–798 (1999).
   PubMed Web of Science ®Google Scholar
• Feldman M, Jialal I, Devaraj D, Cryer B. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J. Am. Coll. Cardiol. 37, 2036–2041 (2001).
   PubMed Web of Science ®Google Scholar
• Takeda T, Hoshida S, Nishino M, Tanouchi J, Otsu K, Hori M. Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. Atherosclerosis 169(1), 155–158 (2003).
   PubMed Web of Science ®Google Scholar
• Chew DP, Bhatt DL, Robbins MA et al. Effects of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am. J. Cardiol. 88, 672–674 (2001).
   PubMed Web of Science ®Google Scholar
• Tsikouris JP, Cox CD. Pharmacologic blockade of the renin-angiotensin system: vascular benefits beyond commonly understood pharmacologic actions. Pharmacotherapy 23(9), 1141–1152 (2003).
   PubMed Web of Science ®Google Scholar
• Kranzhöfer R, Schmidt J, Pfeiffer CAH, Hagl S, Libby P, Kübler W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol.19, 1623–1629 (1999).
   PubMed Web of Science ®Google Scholar
• Bünte C, Witte J, Hoeper K, Schieffer B. Contrasting anti-atherosclerotic effects of AT1-antagonism and ACE inhibition in patients with coronary artery disease: potential impact on plaque passivation. Circulation 19, II-337 (2002) (Abstract 1684).
   Google Scholar
• Takeda T, Hoshida S, Nishino M, Tanouchi J, Otsu K, Hori M. Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. Atherosclerosis 169(1), 155–158 (2003).
   PubMed Web of Science ®Google Scholar
• Andersen S, Schalkwijk CG, Stehouwer CDA, Parving HH. Angiotensin II blockade is associated with decreased plasma leukocyte adhesion molecule levels in diabetic nephropathy [letter]. Diabetes Care 23, 1032–1032 (2000).
   Google Scholar
• Ridker PM, Rifai N, Pfeffer MA et al. for the Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 98, 839–844 (1998).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E; for the Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 100, 230–235 (1999).
   PubMed Web of Science ®Google Scholar
• Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 286, 64–70 (2001).
   PubMed Web of Science ®Google Scholar
• Costa A, Casamitjana R, Casals E et al. Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose. Diabet. Med. 20, 743–745 (2003).
   Google Scholar
• Kinlay S, Timms T, Clark M et al. Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischaemia. Am. J. Cardiol. (89) 1205–1207 (2002).
   PubMed Web of Science ®Google Scholar
• Sowers JR. Effects of statins on the vasculature: implications for aggressive lipid management in the cardiovascular metabolic syndrome. Am. J. Cardiol. 91, 14B–22B (2003).
   PubMed Web of Science ®Google Scholar
• Maison P, Mennen L, Sapinho et al. A pharmacoepidemiological assessment of the effect of statins and fibrates on fibrinogen concentration. Atherosclerosis 160, 155–160 (2002).
   PubMed Web of Science ®Google Scholar
• Balk EM, Lau J, Goudas LC et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann. Intern. Med. 139, 670–682 (2003).
   PubMed Web of Science ®Google Scholar
• Jonkers IJ, Mohrschladt MF, Westendorp RG, can der Laarse A, Smelt AH. Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. Am. J. Med. 112(4), 275–280 (2002).
   PubMed Web of Science ®Google Scholar
• Stein JH, Rosenson RS. Treatment of severe hypertriglyceridemia lowers plasma viscosity. Atherosclerosis 137, 401–405 (1998).
   Google Scholar
• Malik J, Melenovsky V, Wichterle D et al. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial – FAT). Cardiovasc. Res. 52, 290–298 (2001).
   PubMed Web of Science ®Google Scholar
• Chesney CM, Herd JA, Elam MB et al. Niacin lowers fibrinogen in patients with peripheral artery disease (PAD). Circulation 94, S84 (1996) (Abstract).
   Google Scholar
• De Jager J, Kooy A, Lehert P et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in Type 2 diabetes mellitus: a randomized, placebo-controlled trial. Intern. Med. 257(1), 100–109 (2005).
   Google Scholar
• Biarnés J, Fernández-Real JM, Fernández-Castaner M, del Mar García M, Soler J, Ricart W. Differential regulation of insulin action and tumor necrosis factor a system activity by metformin. Metab. Clin. Exp. 54, 235–239 (2005).
   Google Scholar
• Caballero AE, Delgado A, Aguilar-Salinas CA et al. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. Clin. Endocrinol. Metabol. 89(8), 3943–3948 (2004).
   Google Scholar
• Haffner SM, Greenberg, Weston WM, Chen H, Williams K, Freed MI. Effects of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with Type 2 diabetes mellitus. Circulation 106, 679–684 (2002).
   PubMed Web of Science ®Google Scholar
• Wang TD, Chen WJ, Jin JW, Chen MF, Lee YT. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome. Am. J. Cardiol. 93(3), 362–365 (2004).
   PubMed Web of Science ®Google Scholar
• Freed MI, Ratner R, Marcovina SM et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in Type 2 diabetes. Am. J. Cardiol. 90, 947–952 (2002).
   PubMed Web of Science ®Google Scholar
• Satoh N, Ogawa Y, Usui T et al. Anti–atherogenic effect of pioglitazone in Type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26(9), 2493–2499 (2003).
   PubMed Web of Science ®Google Scholar
• Chu NV, Kong AP, Kim DD et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with Type 2 diabetes. Diabetes Care 25, 542–549 (2002).
   PubMed Web of Science ®Google Scholar
• Miranda PJ, DeFronzo RA, Califf RM, Guyton JR. Metabolic syndrome: Evaluation of pathological and therapeutic outcomes. Am. Heart J. 149(1), 20–32 (2004).
   Google Scholar
• Koshiyama H, Shimono D, Kuwamura N et al. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in Type 2 diabetes. J. Clin. Endocrinol. Metabol. 86, 3452–3456 (2001).
   PubMed Web of Science ®Google Scholar
• NCEP Expert Panel. Third report of the NCEP expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106, 3143–3421 (2002).
   PubMed Web of Science ®Google Scholar
• Lara-Castro C, Garvey WT. Diet, insulin resistance, and obesity: zoning in on data for Atkins dieters living in South Beach. J. Clin. Endocrinol. Metabol. 89(9), 4197–4205 (2004).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cook NR, Lee IM et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med. 352, 1293–1304 (2005).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Sleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110, 227–239 (2004).
   PubMed Web of Science ®Google Scholar
• Marchetti P, Del Guerra S, Marselli L et al. Pancreatic islets from Type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J. Clin. Endocrinol. Metabol. 89(11) 5535–5541 (2004).
   PubMed Web of Science ®Google Scholar
• Ovalle F, Bell DS. Effect of rosiglitazone versus insulin on the pancreatic beta cell function of subjects with Type 2 diabetes. Diabetes Care 11, 2589–2589 (2004).
   Google Scholar
• UK Prospective DiabetesStudy (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet 352, 854–856 (1998).
   PubMed Web of Science ®Google Scholar